On rare occasions, a dog with mild separation anxiety might benefit
from drug therapy alone, without accompanying behavior modification.
Pets with medical, geriatric, and compulsive disorders may benefit
from drug therapy along with behavioral retraining techniques.
Low cortisol levels can be caused
from drug therapy with androgens or the anti-seizure medication phenytoin.
When outcomes from these two groups were added together, the absence of any benefit
from drug therapy in patients with an unwitnessed arrest may have muted the significant benefit seen in those with a witnessed cardiac arrest, resulting in the marginal overall outcome of the study.»
Not exact matches
A panel of experts which advises the Food and
Drug Administration (FDA) has unanimously voted to recommend approval of a pioneering cancer
therapy from Novartis, setting up a likely approval for the first - of - its - kind treatment.
But for all of the attention paid to its cancer
drug pipeline, Bristol just scored a breakthrough therapy designation from the Food and Drug Administration for a treatment that targets hepatiti
drug pipeline, Bristol just scored a breakthrough
therapy designation
from the Food and
Drug Administration for a treatment that targets hepatiti
Drug Administration for a treatment that targets hepatitis C.
The inspiration for the social - media campaign came
from the recent WHO HIV / AIDS recommendations that stated that «patients should be put on an antiretroviral
therapy of three
drugs immediately after diagnosis» and «everyone at risk of becoming infected should be offered protective doses of similar
drugs.»
These experimental treatments run the gamut
from flu
drugs to cancer medicines to depression
therapies.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results
from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell
therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other
therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data
from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified
from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Abeona Therapeutics (ABEO)- The company announced receipt of Orphan
Drug Designation
from the European Medicines Agency Committee for Orphan Medicinal Products for gene
therapy program ABO - 202.
The startup describes itself as a deep data platform for the study of exosomes, which are small lipid vesicles — air - or fluid - filled cavities — that are excreted
from cells and which deliver information that Mantra plans to use to come up with new
drug therapies.
After suffering
from the terrible side effects of steroids, antibiotics, and immunosuppressant
drug therapy, I decided to do some research of my own and I soon discovered that my symptoms could be controlled simply by the food I put in my body.
This state - of - the - art facility offers comprehensive care and all of the latest infertility treatments, ranging
from in vitro fertilization and artificial insemination to
drug therapies and tubal reversal.
Alcoholics,
Drug - addicts and people suffering
from mental illness into prisons instead of
therapies.
With cutting - edge techniques
from genetics to stem cell
therapy - and life - saving
drugs to prevent, alleviate or cure conditions like Alzheimer's - likely to be developed in the years ahead, what seem medical miracles today will be medically routine tomorrow.
Since the neuronal death can be recapitulated in directly reprogrammed patient neurons, Yoo said the new technique offers a way to study the details of how potential
therapies — including
drugs that are currently being tested in clinical trials — could rescue medium spiny neurons
from death.
A spin - off
from Queen's University 7 years ago, the
drug discovery and development company develops novel cytochrome P450s to generate improved
therapies for skin diseases and cancer.
AveXis, Inc., a clinical - stage gene
therapy company developing treatments for patients suffering from rare and life - threatening neurological genetic diseases, announced in July 2016 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the treatment based on preliminary clinical results from the trial of AVXS
therapy company developing treatments for patients suffering
from rare and life - threatening neurological genetic diseases, announced in July 2016 that the U.S. Food and
Drug Administration (FDA) granted Breakthrough
Therapy Designation for the treatment based on preliminary clinical results from the trial of AVXS
Therapy Designation for the treatment based on preliminary clinical results
from the trial of AVXS - 101.
They can also be used to create novel disease models
from which new
drugs and
therapies can be developed.
He notes his company had planned this year to apply to the U.S. Food and
Drug Administration to use red blood cells and platelets derived
from iPS cells in clinical trials, but «at this point,
therapies with these cells are years off.»
It's one thing to read a dispassionate discussion of whether social and economic pressures have medicalised anxiety, and quite another to read of Stossel's lifelong torture
from overpowering anxiety, despite trying 20 different
therapies and 28 different anti-anxiety
drugs, none of which gave lasting relief.
Although no clinical trials involving
therapies derived
from iPS cells are on the books, researchers are currently testing
drugs on them.
To meet this challenge, researchers are exploring unconventional
therapies,
from electrodes to laser - light stimulation to mind - bending
drugs.
Liu recently received a two - year grant
from the Bright Focus Foundation (brightfocus.org /) that is enabling next - step studies such as exploration of the impact of current
drug therapy on miR - 182.
Currently, Deng's laboratory is conducting additional preclinical studies using the human - derived stem cells
from Down syndrome patients and mouse models to determine whether cellular and behavioral abnormalities can be improved with minocycline
therapy and other candidate
drugs.
The journal provides cutting - edge research including results
from animal models that are likely to apply to patients, studies in human tissue that provide new information about
therapies or disease, and innovative reports of
drug discovery and development.
Biotech claims to be about to deliver dozens of new
drugs and
therapies for everything
from heart disease to cancer.
The researchers hope that ultimately human trials will prove the efficacy of the OH14 compound in sensitising tumour cells and cancer stem cells to existing
drug - based
therapies thus disabling tumours
from seeding new growth after treatment.
Traditionally,
drug therapy for allergy is based on the use of non-sedative antihistamines, i.e. blocking of the histamine H1 receptors, but sometimes additional help is obtained
from blockers of the cysteinyl leukotriene receptor - 1..
But studies
from recent years suggest that tumours harbour
drug - resistant cells long before they encounter
therapy.
Dr Sian Clarke
from the London School of Hygiene & Tropical Medicine, also a principal investigator in the research, said: «This study shows that rapid diagnostic tests can improve the use of artemisinin - based combination
therapies — the most effective treatment for malaria — in
drug shops, but it's not without its challenges.
For example, changes in certain genes could indicate that his cancer was more likely to respond to a particular
drug, while other mutations might predict little benefit
from a specific
therapy.
The new epidermis, grown
from human pluripotent stem cells, offers a cost - effective alternative lab model for testing
drugs and cosmetics, and could also help to develop new
therapies for rare and common skin disorders.
Thereby, physicians would hold a powerful tool,
from which they could benefit in personalised
therapy, this means the administration of a fitting
drug.
Optimism about combination
therapy with artemisinin - related
drugs is tempered by a recent study finding that the malaria parasite may be only one simple mutation away
from becoming resistant to artemisinin.
«With more than 1.7 million people dying globally
from TB each year and the rise of strains that are resistant to
drug treatment, we need a better way to prevent this disease,» said the study's principal investigator Louis Picker, M.D., who is the associate director of the OHSU Vaccine and Gene
Therapy Institute and a professor of pathology, molecular microbiology, and immunology in the OHSU School of Medicine.
That first year on the
drug may provide an optimal window to collect T cells
from patients and subsequently administer a potentially curative T cell
therapy, the authors said.
For the 12 - week, $ 170,000 pilot project, which is funded by the National Institutes of Health (NIH) and will begin later this month, Young's team plans to recruit about 60 patients
from the Ronald Reagan UCLA Medical Center who are experiencing chronic pain, are on long - term opioid
therapy, and have reported other behaviors — such as
drug or alcohol abuse — that put them at high risk of addiction.
Since the inherited risk is based in family genetics and is therefore beyond clinical reach, McFarlane relies on multifamily group
therapy and social supports at school and at work to protect vulnerable patients
from environmental triggers — illicit
drugs and emotional stress in particular — that might send them over the edge.
Marrouche and Johannes Brachmann
from the Klinikum Coburg conducted the eight - year CASTLE - AF clinical trial to compare catheter ablation to conventional
drug therapies recommended by the American Heart Association and European Heart Society to control the heart's rate.
Patients relying on lifesaving
therapies for emergency care and cancer have long - suffered
from stops and starts in
drug manufacturing.
Stopped at a red light on his drive home
from work, Karl Deisseroth contemplates one of his patients, a woman with depression so entrenched that she had been unresponsive to
drugs and electroshock
therapy for years.
Furthermore, in individuals who take medications, the kidney's circadian clock controls the process of
drug elimination
from the body and therefore can influence the duration of a
drug's action and the effectiveness of the
therapy.
«As these
drugs are considerably cheaper than current
therapies, they can improve treatment in the developing world where the number of deaths
from cancer is predicted to increase significantly over the next ten years,» said Dr Federica Sotgia, another leader of the study.
Dr Elliott, who is part - funded by Parkinson's UK, said: «If this kind of
drug proves to be successful in clinical trials, it would have the potential to bring long - lasting relief
from PD symptoms and fewer side effects than existing levadopa
therapy.»
In the past few years alone, researchers have had to backtrack on the health benefits of low - fat, high - fiber diets and the value and safety of hormone replacement
therapy as well as the arthritis
drug Vioxx, which was pulled
from the market after being found to cause heart attacks and strokes in high - risk patients.
Scientists and physicians have tried countless methods to treat the nightmares, anxiety, and flashbacks of posttraumatic stress disorder (PTSD) in soldiers,
from talk
therapy to
drugs designed to press the «delete» button on specific memories.
The finding warrants research into adding
drugs that could prevent the cancer
from hijacking patients» repressive gene regulatory machinery, which might allow the original
therapy to work long enough to eradicate the tumor, the researchers report in their National Institutes of Health - funded study, published in the current issue of Science Translational Medicine.
The researchers caution that the reliable detection of small to moderate risks and benefits of
drug therapies requires cogent data
from large - scale randomized trials designed a priori to test the hypothesis.
A first - of - its - kind gene
therapy received approval
from the Food and
Drug Administration on Tuesday to treat a rare, inherited form of childhood blindness.